Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A compound pharmaceutical composition of adenflowerin and tanshinone Ⅱa and its application

A technology of tanshinone and adenoflavin, which is applied in the field of natural medicines, can solve problems such as unreported effects, achieve good prospects for clinical drug development, strong anti-proliferation activity, and reduce the effects of toxic and side effects

Active Publication Date: 2020-01-07
FOSHAN UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The synergistic effect of ADE and its combination with TSⅡA on lymphoma has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A compound pharmaceutical composition of adenflowerin and tanshinone Ⅱa and its application
  • A compound pharmaceutical composition of adenflowerin and tanshinone Ⅱa and its application
  • A compound pharmaceutical composition of adenflowerin and tanshinone Ⅱa and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1: Using Daudi cells, Raji cells and BC-3 cells to screen and optimize the compound pharmaceutical composition of adenflowerin (ADE) and tanshinone ⅡA (TS ⅡA)

[0022] Take the cells in the logarithmic growth phase and inoculate 3×10 4 Cells / well were placed on a 96-well plate, and after 6 hours of growth, the supernatant was discarded by centrifugation, and then administered according to the following groups: Tumor cells were divided into no-drug group and drug-added group, and TSⅡA and ADE single-drug groups were used in the drug-added group. Group, TSⅡA and ADE combined drug groups with different molar ratios, set 4-6 duplicate wells in each group, culture for 24 hours, discard the supernatant, add 100 μl of MTT (tetrazolium salt) serum-free culture medium containing 0.5 mg / ml for culture After 4 hours, add 100 μl of DMSO (dimethyl sulfoxide), place on a micro-oscillator to vibrate for 10 minutes, and then place on a microplate reader to detect the OD value a...

Embodiment 2

[0028] Embodiment 2: Analysis of the combined administration effect of ADE and TSⅡA

[0029] Based on the Median-effect Principle (moderate effect principle or Chou-Talalay combined index method), the dose-response curve and the combined index curve (fa-C curve) under different effects were drawn using CombiDrug statistical software. The relationship between the effect and the combination index quantitatively evaluates whether there is a synergistic, antagonistic or additive relationship between the two drugs. Specific steps are as follows:

[0030] The drug effect is the inhibition rate (fa)=1-(the average OD570 value of the test group / the average OD570 of the tumor cell blank control group) according to the intermediate effect equation fa / fu=(D / Dm) m , take the logarithm logfa / fu=mlogD–mlogDm on both sides, set a=-mlogDm, b=m, x=logD, y=logfa / fu, and substitute into the intermediate effect equation to get y=bx–a; where fa is the drug effect , fu=1–fa, D is the drug concent...

Embodiment 3

[0035] Example 3: Safety of ADE and TSⅡA on peripheral blood mononuclear lymphocytes

[0036]The safety of TSⅡA and ADE on PBMC cells was evaluated after isolation and culture of mononuclear lymphocytes from healthy volunteers ( figure 1 ): ① draw fresh blood from healthy volunteers into a heparin anticoagulant tube (sterile); then resuspend the cells (sterile) with an equal volume of PBS (or serum-free D-Hank buffer); ② put the suspended cells Add the pre-coated human lymphocyte separation medium (preheated at 37°C), the volume ratio of lymphatic separation medium to cell suspension is not less than 1:1; ③ 500×g (or 2000rpm) horizontal centrifuge for 20-30min, room temperature (20-30°C) at slow speed; ④Discard the upper layer of plasma, carefully suck out the middle white mist layer and add it to 5ml (or 1-2 times the volume) of PBS (or serum-free cell culture buffer), 200×g or 1000rpm Centrifuge for 10 minutes at room temperature (20-30°C) at a slow speed, discard the super...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of natural medicines, and discloses a compound pharmaceutical composition of adenflowerin and tanshinone IIA and its application. The active ingredient of the compound pharmaceutical composition is composed of adenflowerin and tanshinone IIA in a molar ratio of 1:1-1:20. The combination of the two drugs has a strong synergistic effect on treating lymphoma.

Description

technical field [0001] The invention belongs to the field of natural medicines, and discloses a compound pharmaceutical composition of adenflowerin and tanshinone IIA and its application. Background technique [0002] Cancer is a chronic disease that seriously endangers human health, and has become the second largest killer after cardiovascular disease. Therefore, it is of great significance to find safe, effective, and low-toxic antitumor drugs and study their mechanism of action. [0003] Salvia miltiorrhiza is the dry root and rhizome of Salvia miltiorrhiza (salvia) of the dicotyledonous plant Labiatae (labiatae), which is excavated in spring and autumn, removed from the sediment, and dried. Distributed in most parts of the country. Have blood circulation promoting and blood stasis dispelling, stimulate the menstrual flow to relieve pain, clear away heart-fire and relieve restlessness, the effect of cooling blood and eliminating carbuncle. For chest pain and heart pain,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/22A61K31/58A61P35/00
CPCA61K31/22A61K31/58A61P35/00A61K2300/00
Inventor 刘连李雄李亚君刘腾彭咏波刘武昆谢国健
Owner FOSHAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com